<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02818543</url>
  </required_header>
  <id_info>
    <org_study_id>LYC-30937-1002</org_study_id>
    <nct_id>NCT02818543</nct_id>
  </id_info>
  <brief_title>Safety and Pharmacokinetic Study of LYC-30937 in Subjects With Active Ulcerative Colitis</brief_title>
  <official_title>An Open-Label, Single Ascending Dose Study To Evaluate The Pharmacokinetic Profile, Safety and Tolerability of Orally Administered LYC-30937 in Subjects With Active Ulcerative Colitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lycera Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lycera Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study to assess the pharmacokinetic profile in patients with active
      ulcerative colitis and compare it to the experience in healthy volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum observed plasma concentration (Cmax)</measure>
    <time_frame>up to 48 hours</time_frame>
    <description>Measure specified pharmacokinetic parameters pre-dose and out to 48 hours post-dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to maximum observed plasma concentration (Tmax)</measure>
    <time_frame>up to 48 hours</time_frame>
    <description>Measure specified pharmacokinetic parameters pre-dose and out to 48 hours</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of estimated Area Under the Curve (0-inf)</measure>
    <time_frame>up to 48 hours</time_frame>
    <description>Measure specified pharmacokinetic parameters pre-dose and out to 48 hours</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment emergent adverse events (TEAEs)</measure>
    <time_frame>7 days post-dose</time_frame>
    <description>TEAEs will be listed and summarized by dose and overall</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical laboratory data</measure>
    <time_frame>7 days post-dose</time_frame>
    <description>Clinical laboratory data will be listed with flagging of values outside the normal range</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital signs</measure>
    <time_frame>7 days post-dose</time_frame>
    <description>descriptive statistics will be provided to summarize vital signs and changes from baseline by dose at each scheduled time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>12-Lead Electrocardiogram (ECG)</measure>
    <time_frame>7 days post-dose</time_frame>
    <description>Descriptive statistics will be provided to summarize ECG parameters</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LYC-30937 25 mg single oral dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LYC-30937 100 mg single oral dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LYC-30937</intervention_name>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Active ulcerative colitis defined as a Mayo endoscopy score of â‰¥ 2 despite therapy.

          -  Male or female age 18 to 75

          -  May be receiving a therapeutic dose of an oral 5-amino salicylic acid compound or oral
             corticosteroid therapy

        Exclusion Criteria:

          -  Current anti-tumor necrosis factor use

          -  Current immunosuppressant use (Note: this does not include corticosteroid use)

          -  Subjects with only distal active disease (i.e. proctitis)

          -  Clinically significant active infection

          -  Known bleeding disorder, a risk of bleeding or hypercoagulable disorders in which an
             anticoagulant is required

          -  History of malignancy within the last 5 years except non-melanoma skin cancer or
             cervical carcinoma in situ

          -  Clinically significant lab abnormalities (i.e. liver function abnormalities, renal
             insufficiency, abnormal absolute neutrophil count or hemoglobin)

          -  History of colon resection

          -  Any other investigational therapy or investigational biologics use within 8 weeks of
             investigational medicinal product administration
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>DRC Ltd.</name>
      <address>
        <city>Balatonfured</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PRA Magyarorszag Kft</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hungary</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 30, 2016</study_first_submitted>
  <study_first_submitted_qc>June 27, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 29, 2016</study_first_posted>
  <last_update_submitted>December 13, 2016</last_update_submitted>
  <last_update_submitted_qc>December 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 14, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

